FCGRT and myasthenia gravis: FcAbdeg (efgartigimod) is a recently FDA-approved therapeutic that accelerates the depletion of circulating total IgG by possessing enhanced affinity for and saturating FcRn and is currently approved to treat myasthenia gravis (44).